FDA Approved: APREPITANT — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

The FDA approved BluePoint Laboratories' supplemental application for aprepitant (ANDA 207777), allowing a generic version of this antiemetic to be marketed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting
• Postoperative Nausea and Vomiting

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

SUPPL AP for APREPITANT (APREPITANT)